LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

LLY

920.66

+0.74%↑

UNH

591.96

+1.78%↑

NVO

117.12

-0.12%↓

JNJ

160.83

+0.76%↑

ABBV

194.81

+0.93%↑

Kodu・Aktsiate loetelu・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Suletud

Sektor Tervishoid

270.77 -0.1

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

268.53

Max

273

Põhinäitajad
By Trading Economics
Sissetulek	49M -17M
Müük	165M 660M
Aktsiakasum	0.56
Kasumimarginaal	-2.56
Töötajad	2,100
EBITDA	50M 47M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+12.88 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	31. okt 2024

Turustatistika
By TradingEconomics
Turukapital	-579M 34B
Eelmine avamishind	270.87
Eelmine sulgemishind	270.77

Uudiste sentiment

By Acuity

50%

173 / 366 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

271 / 275.1099 Toetus ja vastupanu

Alnylam Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. sept 2024, 17:01 UTC

Peamised uudised

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12. sept 2024, 11:00 UTC

Peamised uudised

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

Alnylam Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

12.88% tõus

12 kuu keskmine prognoos

Keskmine 306.11 USD 12.88%

Kõrge 400 USD

Madal 233 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Alnylam Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

22 ratings

Osta

Hoia

Müü

Põhineb 22 analüütiku instrumendi Alnylam Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

271 / 275.1099Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

173 / 366 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's commercial products and pipeline of investigational RNAi therapeutics are focused in four Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases and CNS/Ocular Diseases. The Company's RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). The ONPATTRO (patisiran) is an intravenously administered RNAi therapeutic targeting Transthyretin Amyloidosis (TTR). The GIVLAARI (givosiran) is used to reduce induced liver aminolevulinic acid synthase 1 mRNA, to reduction of toxins associated with attacks and other disease manifestations of Acute Hepatic Porphyria (AHP). The OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of Primary Hyperoxaluria Type 1 (PH1). The Leqvio (inclisiran) is used for the treatment of adults with hypercholesterolemia.